entertainment -WSS

entertainment

author：knowledge 2025-09-30 16:23:33 - browse：9

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Community Health Systems hospitals under DOJ investigation

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Supreme Court to hear if Covid misinformation is protected speech

WuXi Biologics execs register to lobby as Congress comes for the company

Cherokee Nation medical school graduates its first class

Alabama hospital puts IVF treatments on hold

Fertility clinic egg and embryo storage is a disaster

focus

entertainment

focus

Bright Health sells Medicare Advantage business to Molina

Supreme Court to hear if Covid misinformation is protected speech

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A new nitrogen execution bill also undermines medical licensing

Medical leaders decry Supreme Court decision on affirmative action

The United States must get value

Apple is now the first public company to be valued at $3 trillion

ALS treatment from Biogen, Ionis fails in study

State Dept. review finds Biden bears some blame for Afghanistan failures

Oak Street deal isn't the answer to health care's woes

leisure time

A new nitrogen execution bill also undermines medical licensing

Alabama frozen embryo ruling has major implications for IVF clinics

PBM reform efforts get punted in Congress

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

In utero gene editing: an explainer

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

entertainment

focus

explore